Product image of Mixtard 50 Penfill (Insulin Human) supplied by GNH India

Mixtard 50 Penfill

Active Ingredient:
Insulin Human
Origin:
EU

Mixtard 50 Penfill (Insulin Human)

Insulin Human, the active ingredient in Mixtard 50 Penfill, is an insulin presented as a pre‑filled insulin pen for subcutaneous use. It is used to manage blood glucose levels in patients with diabetes mellitus.
GNH India supplies Mixtard 50 Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novo Nordisk A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mixtard 50 Penfill provides rapid‑acting insulin therapy for diabetes mellitus and related hyperglycaemia.

  • Type 1 diabetes mellitus: improves glycaemic control by replacing deficient endogenous insulin.
  • Type 2 diabetes mellitus: assists in achieving target blood glucose when oral agents are insufficient.
  • Gestational diabetes mellitus (when insulin therapy is required): maintains maternal and fetal glucose homeostasis.

How It Works

  • Insulin Human binds to insulin receptors on cell membranes, activating the receptor’s intrinsic tyrosine kinase activity. This triggers intracellular signaling cascades that promote glucose transporter translocation, increase cellular glucose uptake, enhance glycogen synthesis, and suppress hepatic gluconeogenesis, thereby lowering blood glucose concentrations.

Side Effects

Common Side Effects

  • Hypoglycaemia: low blood glucose levels, often presenting with sweating, tremor, or dizziness.
  • Injection site reactions: redness, swelling, or itching at the injection site.
  • Weight gain: increase in body weight due to improved glucose utilization.
  • Lipodystrophy: localized changes in subcutaneous fat at repeated injection sites.
  • Edema: mild fluid retention, especially in the lower extremities.

Serious or Rare Side Effects

  • Severe hypoglycaemia: neurological impairment, seizures, or loss of consciousness.
  • Allergic reactions: rash, urticaria, or anaphylaxis requiring immediate medical attention.
  • Insulin antibodies: formation of antibodies that may alter insulin efficacy.
  • Hypokalemia: low serum potassium levels, potentially leading to cardiac arrhythmias.
  • Lipohypertrophy: large, firm lumps of fatty tissue that can affect insulin absorption.

Precautions & Warnings

Mixtard 50 Penfill requires careful monitoring and patient education to minimise risks.

  • Blood glucose monitoring: regularly check glucose levels to adjust dosing appropriately.
  • Hypoglycaemia risk: avoid dosing when blood glucose is already low and educate patients on recognising symptoms.
  • Concomitant medications: be aware of drugs that may potentiate or mask hypoglycaemia.
  • Pregnancy and lactation: use only if clearly needed; benefits should outweigh potential risks.
  • Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mixtard 50 Penfill may interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid)

  • Beta‑blockers: can mask hypoglycaemia symptoms, increasing risk.
  • ACE inhibitors: may potentiate insulin’s glucose‑lowering effect.
  • Thiazide diuretics: can enhance hypoglycaemia.
  • Alcohol: may cause unpredictable blood glucose fluctuations.
  • Oral hypoglycaemic agents: additive glucose‑lowering effect, raising hypoglycaemia risk.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: may increase insulin requirements.
  • Thyroid hormones: can alter insulin sensitivity.
  • Growth hormone therapy: may reduce insulin effectiveness.
  • Lipid‑lowering agents (e.g., fibrates): potential for modest glucose changes.
  • Certain antibiotics (e.g., fluoroquinolones): may affect blood glucose control.

Frequently Asked Questions

Mixtard 50 Penfill contains human insulin and is used to control blood glucose levels in patients with type 1 or type 2 diabetes mellitus. It provides rapid‑acting insulin replacement to help achieve target glycaemic goals as part of a comprehensive diabetes management plan.

Insulin Human binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake, promote glycogen storage, and suppress hepatic glucose production. This coordinated action lowers circulating glucose and restores metabolic balance.

The dose of Mixtard 50 Penfill is individualized. A qualified prescriber determines the amount based on the patient’s blood glucose readings, carbohydrate intake, activity level and overall treatment goals. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for Insulin Human in pregnancy and lactation are limited. It may be used when clearly needed, but the prescriber must weigh potential benefits against any unknown risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss insulin therapy with their obstetric and diabetes care providers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and the necessary import documentation.

Mixtard 50 Penfill delivers human insulin in a pre‑filled pen, offering convenience similar to other rapid‑acting insulin analogues. Unlike some analogues, it contains regular human insulin, which may have a slightly different onset and duration profile. Choice of product depends on clinical response, patient preference and prescriber judgment.

Store the pen at 2‑8 °C (refrigerated) and protect it from light. Do not freeze or shake the pen. Once in use, the pen may be kept at room temperature (up to 30 °C) for a maximum of 28 days, after which it should be discarded.

Mixtard 50 Penfill is administered subcutaneously using the pre‑filled pen. The injection site should be rotated among the abdomen, thigh, or upper arm. Patients should follow the pen’s instructions for dose setting, injection technique, and disposal of used needles.

The most serious risks include severe hypoglycaemia, which can lead to seizures or loss of consciousness, and allergic reactions such as anaphylaxis. Patients should be educated to recognise early signs of low blood glucose and to seek immediate medical help if a severe reaction occurs.

Mixtard 50 Penfill should be avoided in individuals with a known hypersensitivity to human insulin or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycaemia at the time of dosing. Clinical judgment is required for patients with unstable cardiovascular conditions or severe renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Human

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT